BRPI0414622A - métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias - Google Patents

métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Info

Publication number
BRPI0414622A
BRPI0414622A BRPI0414622-0A BRPI0414622A BRPI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A
Authority
BR
Brazil
Prior art keywords
compound
pain treatment
methods
treatment methods
acute
Prior art date
Application number
BRPI0414622-0A
Other languages
English (en)
Inventor
Audra L Scully
Robert E Davis
Kimberly E Vanover
Luis Roberto Gardell
Jelveh Lameh
Nicholas Michael Kelly
Fabio Bertozzi
Vladimir Sherbukhin
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of BRPI0414622A publication Critical patent/BRPI0414622A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

"MéTODOS DE IDENTIFICAçãO DE COMPOSTOS, MéTODO DE SELEçãO DE COMPOSTO, MéTODOS DE TRATAMENTO DE DORES AGUDAS E CRÈNICAS, COMPOSTOS E MéTODOS DE TRATAMENTO DE DORES NEUROPáTICAS OU INFLAMATóRIAS". A invenção descrita abaixo refere-se à descoberta do subtipo receptor de neuropeptídeo FF que media a nocicepção aguda e dores neuropáticas crónicas, compostos que interagem seletivamente com esse subtipo receptor e métodos de tratamento de dores agudas e dores neuropáticas crónicas.
BRPI0414622-0A 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias BRPI0414622A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50613003P 2003-09-25 2003-09-25
US50800803P 2003-10-02 2003-10-02
PCT/US2004/031530 WO2005031000A2 (en) 2003-09-25 2004-09-24 Treating neuropathic pain with neuropeptide ff receptor 2 agonists

Publications (1)

Publication Number Publication Date
BRPI0414622A true BRPI0414622A (pt) 2006-11-07

Family

ID=34396293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414622-0A BRPI0414622A (pt) 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Country Status (11)

Country Link
US (1) US20050136444A1 (pt)
EP (1) EP1687641A2 (pt)
JP (1) JP2007506435A (pt)
KR (1) KR20060088885A (pt)
AU (1) AU2004276812A1 (pt)
BR (1) BRPI0414622A (pt)
CA (1) CA2539753A1 (pt)
IL (1) IL174517A0 (pt)
MX (1) MXPA06003276A (pt)
RU (1) RU2006113941A (pt)
WO (1) WO2005031000A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029773A1 (en) * 2004-05-24 2010-02-04 Ludwig-Maximilians-Universitat Munchen Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift)
WO2008014266A2 (en) * 2006-07-24 2008-01-31 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
EP2081562B1 (en) 2006-09-20 2016-02-24 The Board of Regents of The University of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
WO2009094459A1 (en) 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CN102573993A (zh) * 2009-07-31 2012-07-11 Anamar股份公司 治疗炎症的化合物
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
NZ713621A (en) * 2013-05-01 2020-07-31 Neoculi Pty Ltd Compounds and methods of treating infections
KR20170027737A (ko) 2014-07-02 2017-03-10 인플렉티스 바이오사이언스 O-알킬-벤질리덴구아니딘 유도체 및 미스폴딩된 단백질의 축적 관련 장애의 치료를 위한 치료 용도
CN107074752B (zh) 2014-07-02 2021-10-26 英费列特斯生命科学公司 苯亚甲基胍衍生物在治疗蛋白质构象紊乱方面的治疗用途
MX379437B (es) * 2015-04-08 2025-03-10 Res & Innovation Uk Derivados de hidrazina-bencilo sustituidos, como inhibidores de ppp1r15a y ppp1r15b, y el uso de los mismos para el tratamiento de trastorno de proteostasis.
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
JP7153653B2 (ja) 2017-02-14 2022-10-14 リサーチ トライアングル インスティテュート プロリン系神経ペプチドｆｆ受容体モジュレーター
WO2019215470A1 (en) 2018-05-09 2019-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
CA2233584A1 (en) * 1997-06-11 1998-12-11 Smithkline Beecham Corporation 7tm receptor hlwar77
US6262246B1 (en) * 1998-09-25 2001-07-17 Synaptic Pharmaceutical Corporation DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
US20030176314A1 (en) * 2001-09-24 2003-09-18 Forray Carlos C. Compounds for the treatment of pain
AU2003216866A1 (en) * 2002-04-02 2003-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)

Also Published As

Publication number Publication date
CA2539753A1 (en) 2005-04-07
JP2007506435A (ja) 2007-03-22
KR20060088885A (ko) 2006-08-07
WO2005031000A2 (en) 2005-04-07
WO2005031000A3 (en) 2005-07-14
MXPA06003276A (es) 2006-06-08
US20050136444A1 (en) 2005-06-23
AU2004276812A1 (en) 2005-04-07
IL174517A0 (en) 2006-08-01
EP1687641A2 (en) 2006-08-09
RU2006113941A (ru) 2007-10-27

Similar Documents

Publication Publication Date Title
FR21C1031I1 (pt)
EA200300933A1 (ru) Новое применение соединения из класса пептидов для лечения аллодинии или других различных типов хронической или фантомной боли
MA30673B1 (fr) Composes et procedes d'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
DE122009000053I1 (de) Verwendung einer peptidartigen verbindung zur behandlung von neuropathischen entzündlichen schmerzerscheinungen
WO2003048207A3 (en) Anti-dota antibody
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP2119443A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO A THROMBUS OR EMBOLUS
BR0111567A (pt) Ligandos do receptor de melanocortina
BRPI0516533A (pt) método para o tratamento, inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero que dele necessita; produto; uso de um composto inibidor da tace; composição farmacêutica para o tratamento, a inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
WO2005031000A3 (en) Treating neuropathic pain with neuropeptide ff receptor 2 agonists
FR2847020B1 (fr) Conduit structurel composite de traitement ou d'acheminement de fluide
DK1397164T3 (da) Lukkeelement
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
FR2886516B1 (fr) Procede de traitement antigerminatif et/ou biocide de bulbes ou tubercules au moyen de cipc et d'un terpene ou d'une huile terpenique
DE60039999D1 (de) Bindungsoberfläche
MA26252A1 (fr) Usine flottante de traitement d'hydrocarbures.
DE50112878D1 (de) Nachweis von pathogenen bakterien
HU0201394D0 (pt)
SE0302361D0 (sv) Inhibering av upptagning av monoamin
BRPI0412512A (pt) método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina
WO2002083112A3 (en) Method for the treatment of polycystic kidney disease
ATE455270T1 (de) Korrosionsbeständige leitungssysteme mit verbesserter oberflächenhärte
MA24917A1 (fr) Machine electromecanique pour l'injection d'enduit, fait pour la construction d'immeubles.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.